Compare Adaptive Biotechnologies Corp (ADPT) vs Mesoblast Limited (MESO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Mesoblast Limited — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Mesoblast Limited trades at $14.81 (market cap $1.82B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| ADPT | MESO | |
|---|---|---|
Market Cap | $3.33B | $1.82B |
Sector | Health | Technology |
52-Week High | $22.37 | $20.96 |
52-Week Low | $10.24 | $10.45 |
Enterprise Value | $3.19B | $1.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $14.33, down 0.35% with a bearish technical signal. The company reported Q1 2025 revenue of $17.20M with a gross margin of 80.52% but significant losses (-$102.14M net income). Recent developments include FDA BLA filing for rexlemestrocel-L in heart failure and a $50M debt facility draw. Analyst consensus shows 45% buy ratings amid high valuation multiples (P/S 30.52).
Outlook hinges on regulatory approvals and commercial execution. The stock offers speculative upside from pipeline catalysts but carries substantial risk from cash burn and clinical trial outcomes. Investors face volatility from binary regulatory events while current fundamentals reflect pre-revenue biotech challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
